Astrana Health, Inc. (ASTH)
NASDAQ: ASTH · Real-Time Price · USD
23.18
+0.14 (0.61%)
Dec 1, 2025, 4:00 PM EST - Market closed
Astrana Health Stock Forecast
Stock Price Forecast
The 8 analysts that cover Astrana Health stock have a consensus rating of "Strong Buy" and an average price target of $43, which forecasts a 85.50% increase in the stock price over the next year. The lowest target is $26 and the highest is $56.
Price Target: $43 (+85.50%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Astrana Health stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Maintains $44 → $37 | Strong Buy | Maintains | $44 → $37 | +59.62% | Nov 25, 2025 |
| Barclays | Barclays | Hold Maintains $36 → $26 | Hold | Maintains | $36 → $26 | +12.17% | Nov 24, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $40 → $35 | Strong Buy | Maintains | $40 → $35 | +50.99% | Nov 10, 2025 |
| BTIG | BTIG | Strong Buy Maintains $50 → $45 | Strong Buy | Maintains | $50 → $45 | +94.13% | Nov 7, 2025 |
| Barclays | Barclays | Hold Initiates $36 | Hold | Initiates | $36 | +55.31% | Apr 1, 2025 |
Financial Forecast
Revenue This Year
3.27B
from 2.03B
Increased by 60.87%
Revenue Next Year
4.16B
from 3.27B
Increased by 27.04%
EPS This Year
1.22
from 0.90
Increased by 35.75%
EPS Next Year
2.08
from 1.22
Increased by 70.32%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.4B | 4.4B | ||||
| Avg | 3.3B | 4.2B | ||||
| Low | 3.1B | 3.8B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 68.3% | 35.8% | ||||
| Avg | 60.9% | 27.0% | ||||
| Low | 53.3% | 17.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.43 | 2.69 | |
| Avg | 1.22 | 2.08 | |
| Low | 0.99 | 1.57 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 58.7% | 120.0% | |
| Avg | 35.7% | 70.3% | |
| Low | 10.0% | 28.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.